
Chronic Obstructive Pulmonary Disease (COPD) Market Report and Forecast 2025-2034
Description
The chronic obstructive pulmonary disease (COPD) market size was valued at USD 18.40 Billion in 2024, driven by the increased tobacco consumption across the 7 major markets. The market is expected to grow at a CAGR of 5.30% during the forecast period of 2025-2034, with the values likely to reach USD 30.84 Billion by 2034.
Chronic Obstructive Pulmonary Disease (COPD): Introduction
Chronic obstructive pulmonary disease (COPD) is a common lung disease in which a patient suffers from breathing issues because the airflow gets restricted. It is also known as emphysema or chronic bronchitis. There are chances that lungs may get clogged with phlegm in people suffering from it. The symptoms of chronic obstructive pulmonary disease include cough (with or without phlegm), breathing issues, wheezing, and exhaustion. The most common causes of chronic obstructive pulmonary disease include smoking and air pollution.
Chronic Obstructive Pulmonary Disease (COPD) Market Analysis
The increasing prevalence of chronic obstructive pulmonary disease within the 7 major markets is directly contributing to the chronic obstructive pulmonary disease market demand. The increase in COPD prevalence is due to several factors such as increasing aging population, increased urbanization, and other lifestyle habits. As people age, they are more susceptible to developing COPD due to decreased immunity rates with age. The increasing population of vehicles has been contributing to a rise in pollution levels in the urban cities and with the population density being high, it is directly contributing to the rise in COPD. Additionally, increased involvement of smoking and decreased health maintenance contributes to the rise in number of cases.
The chronic obstructive pulmonary disease market growth is driven by the advent of novel treatment alternatives for patients. In March 2023, Sanofi revealed that their potential COPD drug called Dupixent® showed favourable results in the Phase 3 trials. It is the first and only biologic to demonstrate a 30% reduction in acute as well as moderate exacerbations of COPD.
In addition to pharmacological treatments, surgical interventions like the lung volume reduction surgery, bullectomy and lung transplant are also being used on patients with severe conditions. With the prevalence of personalised treatments and targeted biologics, triple drug combinations that include the use of long-acting beta antagonists (LABAs), long-acting muscarinic antagonists (LAMA), and inhaled steroids are being considered as a valid treatment alternative. As research continues to progress, we can anticipate some significant treatment breakthroughs in the coming years, which will contribute significantly to the chronic obstructive pulmonary disease market share in the future.
Chronic Obstructive Pulmonary Disease (COPD) Market Segmentation
“Chronic Obstructive Pulmonary Disease (COPD) Market Report and Forecast 2025-2034” offers a detailed analysis of the market based on the following segments:
Market Breakup by Treatment Type Bronchodilator Monotherapy Short-Acting Beta-2 Agonists Long-Acting Beta-2 Agonists Others
Anti-Inflammatory Drugs Oral and Inhaled Corticosteroids Anti-Leukotrienes
Others Lung Volume Reduction Surgery
Lung Transplant
Bullectomy
Others
The United States held a substantial portion of the chronic obstructive pulmonary disease market share during the historical period. Factors like a prominent healthcare ecosystem, coupled with core MedTech companies prevailing in the area contributed to the significant market growth. This trend is expected to continue, with the launch of several informative initiatives like the Learn More Breathe Better® Community Subcontract Program, which is organised by the National Heart, Lung, and Blood Institute (NHLBI). This program offers funding to organisations all over the country to offer better health education initiatives.
As a hub of medical inventions, Europe has been a key player in the COPD market. Having significant research and academic institutions along with a well-equipped infrastructure fosters major scope for the development of groundbreaking treatments.
The Asia Pacific region is home to various developing countries undergoing rapid urbanisation. As a result, the population living in the region is more susceptible to developing COPD due to higher exposure to pollution levels. Moreover, countries like Japan and China have a massive size of geriatric population, leaving the countries at an increased risk of facing more COPD cases. Identifying the current trend, the region is experiencing essential infrastructure developments in hospitals and research labs to combat the high chronic obstructive pulmonary disease market demand that may arise in the future.
Chronic Obstructive Pulmonary Disease (COPD) Market: Competitor Landscape
The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
*Please Note:* The report will take 5 business days to complete, after order confirmation.
Chronic Obstructive Pulmonary Disease (COPD): Introduction
Chronic obstructive pulmonary disease (COPD) is a common lung disease in which a patient suffers from breathing issues because the airflow gets restricted. It is also known as emphysema or chronic bronchitis. There are chances that lungs may get clogged with phlegm in people suffering from it. The symptoms of chronic obstructive pulmonary disease include cough (with or without phlegm), breathing issues, wheezing, and exhaustion. The most common causes of chronic obstructive pulmonary disease include smoking and air pollution.
Chronic Obstructive Pulmonary Disease (COPD) Market Analysis
The increasing prevalence of chronic obstructive pulmonary disease within the 7 major markets is directly contributing to the chronic obstructive pulmonary disease market demand. The increase in COPD prevalence is due to several factors such as increasing aging population, increased urbanization, and other lifestyle habits. As people age, they are more susceptible to developing COPD due to decreased immunity rates with age. The increasing population of vehicles has been contributing to a rise in pollution levels in the urban cities and with the population density being high, it is directly contributing to the rise in COPD. Additionally, increased involvement of smoking and decreased health maintenance contributes to the rise in number of cases.
The chronic obstructive pulmonary disease market growth is driven by the advent of novel treatment alternatives for patients. In March 2023, Sanofi revealed that their potential COPD drug called Dupixent® showed favourable results in the Phase 3 trials. It is the first and only biologic to demonstrate a 30% reduction in acute as well as moderate exacerbations of COPD.
In addition to pharmacological treatments, surgical interventions like the lung volume reduction surgery, bullectomy and lung transplant are also being used on patients with severe conditions. With the prevalence of personalised treatments and targeted biologics, triple drug combinations that include the use of long-acting beta antagonists (LABAs), long-acting muscarinic antagonists (LAMA), and inhaled steroids are being considered as a valid treatment alternative. As research continues to progress, we can anticipate some significant treatment breakthroughs in the coming years, which will contribute significantly to the chronic obstructive pulmonary disease market share in the future.
Chronic Obstructive Pulmonary Disease (COPD) Market Segmentation
“Chronic Obstructive Pulmonary Disease (COPD) Market Report and Forecast 2025-2034” offers a detailed analysis of the market based on the following segments:
Market Breakup by Treatment Type
- Drugs
- Surgery
- Oxygen Therapy
- Others
- Emphysema
- Chronic Bronchitis
- Oral
- Inhalation
- Parenteral
- United States
- United Kingdom
- Germany
- France
- Italy
- Spain
- Japan
The United States held a substantial portion of the chronic obstructive pulmonary disease market share during the historical period. Factors like a prominent healthcare ecosystem, coupled with core MedTech companies prevailing in the area contributed to the significant market growth. This trend is expected to continue, with the launch of several informative initiatives like the Learn More Breathe Better® Community Subcontract Program, which is organised by the National Heart, Lung, and Blood Institute (NHLBI). This program offers funding to organisations all over the country to offer better health education initiatives.
As a hub of medical inventions, Europe has been a key player in the COPD market. Having significant research and academic institutions along with a well-equipped infrastructure fosters major scope for the development of groundbreaking treatments.
The Asia Pacific region is home to various developing countries undergoing rapid urbanisation. As a result, the population living in the region is more susceptible to developing COPD due to higher exposure to pollution levels. Moreover, countries like Japan and China have a massive size of geriatric population, leaving the countries at an increased risk of facing more COPD cases. Identifying the current trend, the region is experiencing essential infrastructure developments in hospitals and research labs to combat the high chronic obstructive pulmonary disease market demand that may arise in the future.
Chronic Obstructive Pulmonary Disease (COPD) Market: Competitor Landscape
The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
- GlaxoSmithKline plc (GSK)
- AstraZeneca
- Boehringer Ingelheim
- Novartis
- Teva Pharmaceutical Industries
- Viatris (formerly Mylan)
- Sunovion Pharmaceuticals
- Cipla
- Merck & Co., Inc.
- Vectura Group
- Pfizer Inc.
- Regeneron Pharmaceuticals
- Circassia Pharmaceuticals
- Theravance Biopharma
- Almirall
*Please Note:* The report will take 5 business days to complete, after order confirmation.
Table of Contents
350 Pages
- 1 Preface
- 1.1 Objectives of the Study
- 1.2 Key Assumptions
- 1.3 Report Coverage – Key Segmentation and Scope
- 1.4 Research Methodology
- 2 Executive Summary
- 3 Chronic Obstructive Pulmonary Disease (COPD) Overview
- 3.1 Guidelines and Stages
- 3.2 Pathophysiology
- 3.3 Screening and Diagnosis
- 3.4 Treatment Pathway
- 4 Patient Profile
- 4.1 Patient Profile Overview
- 4.2 Patient Psychology and Emotional Impact Factors
- 4.3 Risk Assessment and Treatment Success Rate
- 5 Chronic Obstructive Pulmonary Disease (COPD) Epidemiology Analysis – 7MM
- 5.1 7MM Epidemiology Scenario Overview (2018-2034)
- 5.2 United States Chronic Obstructive Pulmonary Disease (COPD) Epidemiology Forecast (2018-2034)
- 5.3 EU-4 and United Kingdom Chronic Obstructive Pulmonary Disease (COPD) Epidemiology Forecast (2018-2034)
- 5.3.1 Germany Chronic Obstructive Pulmonary Disease (COPD) Epidemiology Forecast (2018-2034)
- 5.3.2 France Chronic Obstructive Pulmonary Disease (COPD) Epidemiology Forecast (2018-2034)
- 5.3.3 Italy Chronic Obstructive Pulmonary Disease (COPD) Epidemiology Forecast (2018-2034)
- 5.3.4 Spain Chronic Obstructive Pulmonary Disease (COPD) Epidemiology Forecast (2018-2034)
- 5.3.5 United Kingdom Chronic Obstructive Pulmonary Disease (COPD) Epidemiology Forecast (2018-2034)
- 5.4 Japan Chronic Obstructive Pulmonary Disease (COPD) Epidemiology Forecast (2018-2034)
- 6 Chronic Obstructive Pulmonary Disease (COPD) Market Overview – 7MM
- 6.1 Chronic Obstructive Pulmonary Disease (COPD) Market Historical Value (2018-2024)
- 6.2 Chronic Obstructive Pulmonary Disease (COPD) Market Forecast Value (2025-2034)
- 7 Chronic Obstructive Pulmonary Disease (COPD) Market Landscape – 7MM
- 7.1 Chronic Obstructive Pulmonary Disease (COPD)Sclerosis: Developers Landscape
- 7.1.1 Analysis by Year of Establishment
- 7.1.2 Analysis by Company Size
- 7.1.3 Analysis by Region
- 7.2 Chronic Obstructive Pulmonary Disease (COPD)Product Landscape
- 7.2.1 Analysis by Disease Type
- 7.2.2 Analysis by Treatment Type
- 7.2.3 Analysis by Route of Administration
- 8 Chronic Obstructive Pulmonary Disease (COPD)Challenges and Unmet Needs
- 8.1 Treatment Pathway Challenges
- 8.2 Compliance and Drop-Out Analysis
- 8.3 Awareness and Prevention Gaps
- 9 Cost of Treatment
- 10 Chronic Obstructive Pulmonary Disease (COPD) Market Dynamics
- 10.1 Market Drivers and Constraints
- 10.2 SWOT Analysis
- 10.3 Porter’s Five Forces Model
- 10.4 Key Demand Indicators
- 10.5 Key Price Indicators
- 10.6 Industry Events, Initiatives, and Trends
- 10.7 Value Chain Analysis
- 11 Chronic Obstructive Pulmonary Disease (COPD) Market Segmentation – 7MM
- 11.1 Chronic Obstructive Pulmonary Disease (COPD) Market by Treatment Type
- 11.1.1 Market Overview
- 11.1.2 Drugs
- 11.1.2.1 Bronchodilator Monotherapy
- 11.1.2.1.1 Short-Acting Beta-2 Agonists
- 11.1.2.1.2 Long-Acting Beta-2 Agonists
- 11.1.2.1.3 Others
- 11.1.2.2 Anti-Inflammatory Drugs
- 11.1.2.2.1 Oral and Inhaled Corticosteroids
- 11.1.2.2.2 Anti-Leukotrienes
- 11.1.2.2.3 Others
- 11.1.3 Surgery
- 11.1.3.1 Lung Volume Reduction Surgery
- 11.1.3.2 Lung Transplant
- 11.1.3.3 Bullectomy
- 11.1.3.4 Others
- 11.1.4 Oxygen Therapy
- 11.1.5 Others
- 11.1.6 Chronic Obstructive Pulmonary Disease (COPD) Market by Disease Type
- 11.1.6.1 Market Overview
- 11.1.6.2 Emphysema
- 11.1.6.3 Chronic Bronchitis
- 11.1.7 Chronic Obstructive Pulmonary Disease (COPD) Market by Route of Administration
- 11.1.7.1 Market Overview
- 11.1.7.2 Oral
- 11.1.7.3 Inhalation
- 11.1.7.4 Parenteral
- 11.2 Chronic Obstructive Pulmonary Disease (COPD) Market by Region
- 11.2.1 Market Overview
- 11.2.2 United States
- 11.2.3 EU-4 and the United Kingdom
- 11.2.3.1 Germany
- 11.2.3.2 France
- 11.2.3.3 Italy
- 11.2.3.4 Spain
- 11.2.3.5 United Kingdom
- 11.2.4 Japan
- 12 United States Chronic Obstructive Pulmonary Disease (COPD)Market
- 12.1 Chronic Obstructive Pulmonary Disease (COPD) Market Historical Value (2018-2024)
- 12.2 Chronic Obstructive Pulmonary Disease (COPD) Market Forecast Value (2025-2034)
- 12.3 Chronic Obstructive Pulmonary Disease (COPD) Market by Type
- 12.4 Chronic Obstructive Pulmonary Disease (COPD) Market by Treatment Type
- 13 EU-4 and United Kingdom Chronic Obstructive Pulmonary Disease (COPD)Market
- 13.1 Chronic Obstructive Pulmonary Disease (COPD) Market Historical Value (2018-2024)
- 13.2 Chronic Obstructive Pulmonary Disease (COPD) Market Forecast Value (2025-2034)
- 13.3 Germany Chronic Obstructive Pulmonary Disease (COPD) Market Overview
- 13.3.1 Chronic Obstructive Pulmonary Disease (COPD) Market by Type
- 13.3.2 Chronic Obstructive Pulmonary Disease (COPD) Market by Treatment Type
- 13.4 France Chronic Obstructive Pulmonary Disease (COPD) Market Overview
- 13.4.1 Chronic Obstructive Pulmonary Disease (COPD) Market by Type
- 13.4.2 Chronic Obstructive Pulmonary Disease (COPD) Market by Treatment Type
- 13.5 Italy Chronic Obstructive Pulmonary Disease (COPD) Market Overview
- 13.5.1 Chronic Obstructive Pulmonary Disease (COPD) Market by Type
- 13.5.2 Chronic Obstructive Pulmonary Disease (COPD) Market by Treatment Type
- 13.6 Spain Chronic Obstructive Pulmonary Disease (COPD) Market Overview
- 13.6.1 Chronic Obstructive Pulmonary Disease (COPD) Market by Type
- 13.6.2 Chronic Obstructive Pulmonary Disease (COPD) Market by Treatment Type
- 13.7 United Kingdom Chronic Obstructive Pulmonary Disease (COPD) Market Overview
- 13.7.1 Chronic Obstructive Pulmonary Disease (COPD) Market by Type
- 13.7.2 Chronic Obstructive Pulmonary Disease (COPD) Market by Treatment Type
- 14 Japan Chronic Obstructive Pulmonary Disease (COPD)Market
- 14.1 Chronic Obstructive Pulmonary Disease (COPD) Market Historical Value (2018-2024)
- 14.2 Chronic Obstructive Pulmonary Disease (COPD) Market Forecast Value (2025-2034)
- 14.3 Chronic Obstructive Pulmonary Disease (COPD) Market by Type
- 14.4 Chronic Obstructive Pulmonary Disease (COPD) Market by Treatment Type
- 15 Regulatory Framework
- 15.1 Regulatory Overview
- 15.1.1 US FDA
- 15.1.2 EU EMA
- 15.1.3 JAPAN PMDA
- 16 Patent Analysis
- 16.1 Analysis by Type of Patent
- 16.2 Analysis by Publication year
- 16.3 Analysis by Issuing Authority
- 16.4 Analysis by Patent Age
- 16.5 Analysis by CPC Analysis
- 16.6 Analysis by Patent Valuation
- 16.7 Analysis by Key Players
- 17 Grants Analysis
- 17.1 Analysis by year
- 17.2 Analysis by Amount Awarded
- 17.3 Analysis by Issuing Authority
- 17.4 Analysis by Grant Application
- 17.5 Analysis by Funding Institute
- 17.6 Analysis by NIH Departments
- 17.7 Analysis by Recipient Organization
- 18 Clinical Trials Analysis
- 18.1 Analysis by Trial Registration Year
- 18.2 Analysis by Trial Status
- 18.3 Analysis by Trial Phase
- 18.4 Analysis by Therapeutic Area
- 18.5 Analysis by Geography
- 19 Funding and Investment Analysis
- 19.1 Analysis by Funding Instances
- 19.2 Analysis by Type of Funding
- 19.3 Analysis by Funding Amount
- 19.4 Analysis by Leading Players
- 19.5 Analysis by Leading Investors
- 19.6 Analysis by Geography
- 20 Partnerships and Collaborations Analysis
- 20.1 Analysis by Partnership Instances
- 20.2 Analysis by Type of Partnership
- 20.3 Analysis by Leading Players
- 20.4 Analysis by Geography
- 21 Supplier Landscape
- 21.1 GlaxoSmithKline plc (GSK)
- 21.1.1 Financial Analysis
- 21.1.2 Product Portfolio
- 21.1.3 Demographic Reach and Achievements
- 21.1.4 Mergers and Acquisitions
- 21.1.5 Certifications
- 21.2 AstraZeneca
- 21.2.1 Financial Analysis
- 21.2.2 Product Portfolio
- 21.2.3 Demographic Reach and Achievements
- 21.2.4 Mergers and Acquisitions
- 21.2.5 Certifications
- 21.3 Boehringer Ingelheim
- 21.3.1 Financial Analysis
- 21.3.2 Product Portfolio
- 21.3.3 Demographic Reach and Achievements
- 21.3.4 Mergers and Acquisitions
- 21.3.5 Certifications
- 21.4 Novartis
- 21.4.1 Financial Analysis
- 21.4.2 Product Portfolio
- 21.4.3 Demographic Reach and Achievements
- 21.4.4 Mergers and Acquisitions
- 21.4.5 Certifications
- 21.5 Teva Pharmaceutical Industries
- 21.5.1 Financial Analysis
- 21.5.2 Product Portfolio
- 21.5.3 Demographic Reach and Achievements
- 21.5.4 Mergers and Acquisitions
- 21.5.5 Certifications
- 21.6 Viatris (formerly Mylan)
- 21.6.1 Financial Analysis
- 21.6.2 Product Portfolio
- 21.6.3 Demographic Reach and Achievements
- 21.6.4 Mergers and Acquisitions
- 21.6.5 Certifications
- 21.7 Sunovion Pharmaceuticals
- 21.7.1 Financial Analysis
- 21.7.2 Product Portfolio
- 21.7.3 Demographic Reach and Achievements
- 21.7.4 Mergers and Acquisitions
- 21.7.5 Certifications
- 21.8 Cipla
- 21.8.1 Financial Analysis
- 21.8.2 Product Portfolio
- 21.8.3 Demographic Reach and Achievements
- 21.8.4 Mergers and Acquisitions
- 21.8.5 Certifications
- 21.9 Merck & Co., Inc.
- 21.9.1 Financial Analysis
- 21.9.2 Product Portfolio
- 21.9.3 Demographic Reach and Achievements
- 21.9.4 Mergers and Acquisitions
- 21.9.5 Certifications
- 21.10 Vectura Group
- 21.10.1 Financial Analysis
- 21.10.2 Product Portfolio
- 21.10.3 Demographic Reach and Achievements
- 21.10.4 Mergers and Acquisitions
- 21.10.5 Certifications
- 21.11 Pfizer Inc.
- 21.11.1 Financial Analysis
- 21.11.2 Product Portfolio
- 21.11.3 Demographic Reach and Achievements
- 21.11.4 Mergers and Acquisitions
- 21.11.5 Certifications
- 21.12 Regeneron Pharmaceuticals
- 21.12.1 Financial Analysis
- 21.12.2 Product Portfolio
- 21.12.3 Demographic Reach and Achievements
- 21.12.4 Mergers and Acquisitions
- 21.12.5 Certifications
- 21.13 Circassia Pharmaceuticals
- 21.13.1 Financial Analysis
- 21.13.2 Product Portfolio
- 21.13.3 Demographic Reach and Achievements
- 21.13.4 Mergers and Acquisitions
- 21.13.5 Certifications
- 21.14 Theravance Biopharma
- 21.14.1 Financial Analysis
- 21.14.2 Product Portfolio
- 21.14.3 Demographic Reach and Achievements
- 21.14.4 Mergers and Acquisitions
- 21.14.5 Certifications
- 21.15 Almirall
- 21.15.1 Financial Analysis
- 21.15.2 Product Portfolio
- 21.15.3 Demographic Reach and Achievements
- 21.15.4 Mergers and Acquisitions
- 21.15.5 Certifications
- 22 Chronic Obstructive Pulmonary Disease (COPD)Market- Distribution Model (Additional Insight)
- 22.1 Overview
- 22.2 Potential Distributors
- 22.3 Key Parameters for Distribution Partner Assessment
- 23 Key Opinion Leaders (KOL) Insights (Additional Insight)
- 24 Company Competitiveness Analysis (Additional Insight)
- 24.1 Very Small Companies
- 24.2 Small Companies
- 24.3 Mid-Sized Companies
- 24.4 Large Companies
- 24.5 Very Large Companies
- 25 Payment Methods (Additional Insight)
- 25.1 Government Funded
- 25.2 Private Insurance
- 25.3 Out-of-Pocket
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.